CN114846028B - 抗cd45抗体及其结合物 - Google Patents
抗cd45抗体及其结合物Info
- Publication number
- CN114846028B CN114846028B CN202080086243.5A CN202080086243A CN114846028B CN 114846028 B CN114846028 B CN 114846028B CN 202080086243 A CN202080086243 A CN 202080086243A CN 114846028 B CN114846028 B CN 114846028B
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- adc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202511554650.5A CN121574249A (zh) | 2019-11-01 | 2020-10-30 | 抗cd45抗体及其结合物 |
Applications Claiming Priority (27)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962929194P | 2019-11-01 | 2019-11-01 | |
| US201962929288P | 2019-11-01 | 2019-11-01 | |
| US201962929283P | 2019-11-01 | 2019-11-01 | |
| US201962929347P | 2019-11-01 | 2019-11-01 | |
| US201962929601P | 2019-11-01 | 2019-11-01 | |
| US201962929207P | 2019-11-01 | 2019-11-01 | |
| US201962929137P | 2019-11-01 | 2019-11-01 | |
| US62/929,194 | 2019-11-01 | ||
| US62/929,137 | 2019-11-01 | ||
| US62/929,347 | 2019-11-01 | ||
| US62/929,283 | 2019-11-01 | ||
| US62/929,288 | 2019-11-01 | ||
| US62/929,207 | 2019-11-01 | ||
| US62/929,601 | 2019-11-01 | ||
| US201962940742P | 2019-11-26 | 2019-11-26 | |
| US62/940,742 | 2019-11-26 | ||
| US202062978147P | 2020-02-18 | 2020-02-18 | |
| US62/978,147 | 2020-02-18 | ||
| US202063015348P | 2020-04-24 | 2020-04-24 | |
| US63/015,348 | 2020-04-24 | ||
| US202063046164P | 2020-06-30 | 2020-06-30 | |
| US202063046046P | 2020-06-30 | 2020-06-30 | |
| US63/046,164 | 2020-06-30 | ||
| US63/046,046 | 2020-06-30 | ||
| US202063084903P | 2020-09-29 | 2020-09-29 | |
| US63/084,903 | 2020-09-29 | ||
| PCT/US2020/058373 WO2021087368A2 (en) | 2019-11-01 | 2020-10-30 | Anti-cd45 antibodies and conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202511554650.5A Division CN121574249A (zh) | 2019-11-01 | 2020-10-30 | 抗cd45抗体及其结合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114846028A CN114846028A (zh) | 2022-08-02 |
| CN114846028B true CN114846028B (zh) | 2025-11-14 |
Family
ID=75715351
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080086243.5A Active CN114846028B (zh) | 2019-11-01 | 2020-10-30 | 抗cd45抗体及其结合物 |
| CN202511554650.5A Pending CN121574249A (zh) | 2019-11-01 | 2020-10-30 | 抗cd45抗体及其结合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202511554650.5A Pending CN121574249A (zh) | 2019-11-01 | 2020-10-30 | 抗cd45抗体及其结合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12570756B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4051711A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7716399B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220091567A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114846028B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020376934A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022008371A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3156740A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292628A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005249A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI904109B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021087368A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019374055B2 (en) * | 2018-10-30 | 2026-06-11 | Regeneron Pharmaceuticals, Inc. | Methods for allogeneic hematopoietic stem cell transplantation |
| AU2019370367A1 (en) | 2018-10-30 | 2021-06-17 | Magenta Therapeutics, Inc. | Anti-CD45 antibodies and conjugates thereof |
| AU2020376934A1 (en) | 2019-11-01 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Anti-CD45 antibodies and conjugates thereof |
| WO2023235772A2 (en) * | 2022-05-31 | 2023-12-07 | Fred Hutchinson Cancer Center | Humanized anti-cd45 antibodies and uses thereof |
| WO2024064771A1 (en) * | 2022-09-20 | 2024-03-28 | Vor Biopharma Inc. | Anti-cd45-ign antibody drug conjugates and uses thereof |
| EP4637928A1 (en) * | 2022-12-23 | 2025-10-29 | Cimeio Therapeutics AG | Antibodies targeting cd45 |
| WO2025064944A1 (en) * | 2023-09-20 | 2025-03-27 | Vor Biopharma Inc. | Anti-cd45 antibody-drug conjugate pharmaceutical compositions |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| CN120554516B (zh) * | 2025-07-30 | 2025-10-24 | 杭州华大生命科学研究院 | 抗cd45抗体及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019129178A1 (zh) * | 2017-12-29 | 2019-07-04 | 上海白泽医学检验所有限公司 | 一种含抗cd45单抗的组合物及其使用方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112661B1 (en) * | 1998-10-30 | 2006-09-26 | The Research Foundation Of State University Of New York | Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha |
| AU2006315825A1 (en) * | 2005-11-10 | 2007-05-24 | Receptor Biologix, Inc. | Hepatocyte growth factor intron fusion proteins |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| CA2660286A1 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| CA2674382C (en) * | 2007-01-03 | 2016-05-31 | Morphotek, Inc. | High affinity antibodies that neutralize staphylococcus enterotoxin b |
| UY30994A1 (es) * | 2007-04-02 | 2008-11-28 | Amgen Fremont Inc | Anticuerpos anti-ige |
| US9243057B2 (en) * | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| CN107287660A (zh) * | 2011-09-30 | 2017-10-24 | 中外制药株式会社 | 离子浓度依赖性结合分子文库 |
| CN104178454B (zh) * | 2013-05-24 | 2019-03-08 | 益善生物技术股份有限公司 | 一种循环肿瘤细胞的富集、分析方法 |
| JP6815331B2 (ja) * | 2015-04-21 | 2021-01-20 | ジェネンテック, インコーポレイテッド | 前立腺がんの分析のための組成物及び方法 |
| GB201601073D0 (en) * | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| RS65120B1 (sr) | 2015-11-25 | 2024-02-29 | Immunogen Inc | Farmaceutske formulacije i postupci za njihovu upotrebu |
| CA3016901C (en) | 2016-03-07 | 2023-06-13 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
| CN109641051A (zh) * | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| US20200306301A1 (en) * | 2017-07-03 | 2020-10-01 | Torque Therapeutics, Inc. | Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof |
| US20200376135A1 (en) | 2018-10-23 | 2020-12-03 | Magenta Therapeutics, Inc. | Fc silenced antibody drug conjugates (adcs) and uses thereof |
| CN113330026A (zh) | 2018-10-23 | 2021-08-31 | 美真达治疗公司 | Fc沉默的抗体药物缀合物(ADC)及其用途 |
| AU2019370367A1 (en) * | 2018-10-30 | 2021-06-17 | Magenta Therapeutics, Inc. | Anti-CD45 antibodies and conjugates thereof |
| AU2020376934A1 (en) | 2019-11-01 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Anti-CD45 antibodies and conjugates thereof |
| KR20220154676A (ko) * | 2020-02-18 | 2022-11-22 | 마젠타 테라퓨틱스 인코포레이티드 | 동종 이식을 위한 조성물 및 방법 |
-
2020
- 2020-10-30 AU AU2020376934A patent/AU2020376934A1/en active Pending
- 2020-10-30 CN CN202080086243.5A patent/CN114846028B/zh active Active
- 2020-10-30 BR BR112022008371A patent/BR112022008371A2/pt unknown
- 2020-10-30 CA CA3156740A patent/CA3156740A1/en active Pending
- 2020-10-30 KR KR1020227018323A patent/KR20220091567A/ko active Pending
- 2020-10-30 EP EP20880619.0A patent/EP4051711A4/en active Pending
- 2020-10-30 CN CN202511554650.5A patent/CN121574249A/zh active Pending
- 2020-10-30 JP JP2022525948A patent/JP7716399B2/ja active Active
- 2020-10-30 IL IL292628A patent/IL292628A/en unknown
- 2020-10-30 WO PCT/US2020/058373 patent/WO2021087368A2/en not_active Ceased
- 2020-10-30 TW TW109137991A patent/TWI904109B/zh active
- 2020-10-30 MX MX2022005249A patent/MX2022005249A/es unknown
-
2021
- 2021-10-22 US US17/452,028 patent/US12570756B2/en active Active
-
2024
- 2024-03-07 US US18/598,342 patent/US12209135B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019129178A1 (zh) * | 2017-12-29 | 2019-07-04 | 上海白泽医学检验所有限公司 | 一种含抗cd45单抗的组合物及其使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN121574249A (zh) | 2026-02-27 |
| WO2021087368A3 (en) | 2021-06-10 |
| IL292628A (en) | 2022-07-01 |
| EP4051711A2 (en) | 2022-09-07 |
| AU2020376934A1 (en) | 2022-06-02 |
| TWI904109B (zh) | 2025-11-11 |
| CA3156740A1 (en) | 2021-05-06 |
| US20220267441A1 (en) | 2022-08-25 |
| CN114846028A (zh) | 2022-08-02 |
| MX2022005249A (es) | 2022-07-12 |
| US20240254251A1 (en) | 2024-08-01 |
| JP2022553839A (ja) | 2022-12-26 |
| KR20220091567A (ko) | 2022-06-30 |
| BR112022008371A2 (pt) | 2022-07-12 |
| US12570756B2 (en) | 2026-03-10 |
| JP7716399B2 (ja) | 2025-07-31 |
| WO2021087368A2 (en) | 2021-05-06 |
| US12209135B2 (en) | 2025-01-28 |
| EP4051711A4 (en) | 2024-02-21 |
| TW202132339A (zh) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7669269B2 (ja) | 抗-cd45抗体及びそのコンジュゲート | |
| JP7709376B2 (ja) | Fcサイレンス化抗体薬物コンジュゲート(ADC)及びその使用 | |
| TWI904109B (zh) | 抗cd45抗體及其結合物 | |
| WO2019084057A2 (en) | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS | |
| US20240075157A1 (en) | Fc silenced antibody drug conjugates (adcs) and uses thereof | |
| JP2025172753A (ja) | 自己免疫疾患を治療するための方法および組成物 | |
| CN113490504A (zh) | 抗-cd45抗体药物缀合物(adc)在细胞疗法中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20250605 Address after: The American state of Massachusetts Applicant after: VOR biopharmaceutical Co.,Ltd. Country or region after: U.S.A. Address before: Massachusetts, USA Applicant before: MAGENTA THERAPEUTICS, Inc. Country or region before: U.S.A. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20260318 Address after: New York State, USA Patentee after: REGENERON PHARMACEUTICALS, Inc. Country or region after: U.S.A. Address before: The American state of Massachusetts Patentee before: VOR biopharmaceutical Co.,Ltd. Country or region before: U.S.A. |